Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)

Dermatofibrosarcoma protuberans (DFSP) is a low-to-intermediate grade sarcoma with a reported incidence of 4.1 per million person-years. Despite its local invasiveness, it rarely metastasizes (5% of cases). Fibrosarcomatous change in DFSP is a form of tumor progression that carries an increased risk...

Full description

Saved in:
Bibliographic Details
Main Author: Ivo Klarin
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Case Reports in Gastrointestinal Medicine
Online Access:http://dx.doi.org/10.1155/2023/1057247
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849700432133226496
author Ivo Klarin
author_facet Ivo Klarin
author_sort Ivo Klarin
collection DOAJ
description Dermatofibrosarcoma protuberans (DFSP) is a low-to-intermediate grade sarcoma with a reported incidence of 4.1 per million person-years. Despite its local invasiveness, it rarely metastasizes (5% of cases). Fibrosarcomatous change in DFSP is a form of tumor progression that carries an increased risk of metastases. We reported a case of 45-year-old patient treated with adalimumab lasting 7 years for Crohn’s disease who developed dermatofibrosarcoma protuberans with fibromatous changes. Adalimumab therapy was stopped before surgery, and ustekinumab was introduced 6 months after.
format Article
id doaj-art-6728f85fdac94165a6fc3da4bd84d561
institution DOAJ
issn 2090-6536
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Case Reports in Gastrointestinal Medicine
spelling doaj-art-6728f85fdac94165a6fc3da4bd84d5612025-08-20T03:18:15ZengWileyCase Reports in Gastrointestinal Medicine2090-65362023-01-01202310.1155/2023/1057247Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)Ivo Klarin0General Hospital ZadarDermatofibrosarcoma protuberans (DFSP) is a low-to-intermediate grade sarcoma with a reported incidence of 4.1 per million person-years. Despite its local invasiveness, it rarely metastasizes (5% of cases). Fibrosarcomatous change in DFSP is a form of tumor progression that carries an increased risk of metastases. We reported a case of 45-year-old patient treated with adalimumab lasting 7 years for Crohn’s disease who developed dermatofibrosarcoma protuberans with fibromatous changes. Adalimumab therapy was stopped before surgery, and ustekinumab was introduced 6 months after.http://dx.doi.org/10.1155/2023/1057247
spellingShingle Ivo Klarin
Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)
Case Reports in Gastrointestinal Medicine
title Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)
title_full Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)
title_fullStr Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)
title_full_unstemmed Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)
title_short Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)
title_sort dermatofibrosarcoma protuberans dfsp with fibrosarcomatous changes in a patient with crohn s disease treated with anti tnf adalimumab
url http://dx.doi.org/10.1155/2023/1057247
work_keys_str_mv AT ivoklarin dermatofibrosarcomaprotuberansdfspwithfibrosarcomatouschangesinapatientwithcrohnsdiseasetreatedwithantitnfadalimumab